一电力企业男性职工脂肪肝检出情况及影响因素分析研究*

doi:10.3969/j.issn.1672-5069.2025.03.039

Abstract

Dang Xuejuan, Xie Xiaoyan, Tang Ping, et al. Prevalence and influencing factors of fatty liver in male employees: A single centre of investigation in a power enterprise[J]. Journal of Practical Hepatology, 2025, 28(3): 474-476.

References

[1] 中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版).实用肝脏病杂志,2024,27(4): 494-510.
[2] 娄莹,马文君,王子君,等.中国高血压临床实践指南计划书.中华心血管病杂志,2022,50 (7):671-675.
[3] 王增武,刘静,李建军,等.中国血脂管理指南(2023年).中国循环杂志,2023,38 (3):237-271.
[4] 中华中医药学会糖尿病基层防治专家指导委员会.国家糖尿病基层中医防治管理指南(2022年).中华糖尿病杂志,2023,15(2):100-117.
[5] 中国医师协会肾脏内科医师分会.中国肾脏疾病高尿酸血症诊治的实践指南(2017年版).中华医学杂志,2017,97(25):1927-1936.
[6] Younossi ZM,Koenig AB,Abdelatif D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta -analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016,64(1):73-84.
[7] 范能光,彭亮,夏振华,等.正常血清尿酸与非酒精性脂肪性肝病的相关性研究.中国糖尿病杂志,2017,25(11):970-973.
[8] Paik JM , Kabbara K , Eberly KE ,et al.Global burden of non-alcoholic fatty liver disease (NAFLD) and chronic liver disease (CLD) among adolescents and young adults. Hepatology,2022,75(5):1204-1217.
[9] Erard D, Villeret F, Chouik Y, et al. Dual alcohol and metabolic-related liver disease: Results from a population of liver transplant patients. Liver Int, 2024, 44(2): 422-432.
[10] Vusirikala A, Thomas T, Bhala N, et al. Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): A United Kingdom population-based cohort study using the health improvement network (THIN). BMC Endocr Disord, 2020,30;20(1):96.
[11] Pirola CJ, Sookoian S. Non-alcoholic fatty liver disease mediates the effect of obesity on arterial hypertension. Liver Int, 2023, 43(10): 2167-2176.
[12] Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. J Lipid Res, 2020, 61(4): 470-479.

[1]	Chen Chunru, Qi Haolong, Lu Cong, et al. Impact of circadian rhythms on pathogenesis of non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 321-325.
[2]	Lu Yifan, Chen Hao, Huai Jiaxian, et al. Hashimoto's thyroiditis and nonalcoholic fatty liver disease:contingency or causality? [J]. Journal of Practical Hepatology, 2025, 28(3): 326-329.
[3]	Liu Qian, Yang Jie, Zhang Jing, et al. Implication of peripheral blood mononuclear cell galectin-3 and galectin-9 in patients with chronic hepatitis B and concomitant metabolism-related fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 338-341.
[4]	Dai Zixing, Yuan Hui, Chen Qingling, et al. Correlation of serum volatile organic compounds to body inflammatory index in patients with metabolism-related fatty liver disease: an analysis based on 2017-2020 National Health and Nutrition Examination Survey database [J]. Journal of Practical Hepatology, 2025, 28(3): 350-353.
[5]	Wei Taotao, Liu Tianye, Dai Gaozhong. Characterization of ileal microbiome in patients with metabolic-associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 354-357.
[6]	Dong Xu, Wang Chaoqun, Chen Yi, et al. Efficacy of estimated glucose disposal rate in predicting risk of metabolism-associated fatty liver disease in individuals without diabetes [J]. Journal of Practical Hepatology, 2025, 28(3): 362-365.
[7]	Qin Hao, Fang Chunhua, He Jing, et al. Comparison of diagnostic performance of six non-invasive evaluation scores for type 2 diabetes mellitus with metabolic associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 366-369.
[8]	Wen Dachao, Zhang Qiuping, Shi Ling. Short-term observation of acupoint application and exercise in the treatment of patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 370-373.
[9]	Ma Chengxi, Xu Jing, Wang Yanqiu. Ultrasound attenuation coefficient and serumALT/AST ratio in evaluating liver steatosis in patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 374-377.
[10]	Wang Xintian, Kang Xiaobo, Wu Xia, et al. Changes of serum osteocalcin,β-I type collagen carboxy-terminal peptide and angiotensin levels in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2025, 28(3): 378-381.
[11]	Zeng Ai, Wang Cong, Li Min, et al. Diagnostic performance of shear wave elastography and APRI combination in predicting significant liver fibrosis in patients with type 2 diabetes mellitus and NAFLD [J]. Journal of Practical Hepatology, 2025, 28(3): 382-385.
[12]	Liu Qianqian, Duan Zhijiao, Chen Ping. Non-invasive assessment of liver fibrosis in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 477-480.
[13]	Wang Xiaoyan, Cui Wenxing, Chen Chao. Controlled attenuation parameter, liver stiffness measurement and total adipose tissue in screening patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(2): 198-201.
[14]	Han Yue, Zhai Feifei, Zhang Qing, et al. Diagnostic performance of ultrasound attenuation imaging coefficient in predicting hepatic steatosis in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(2): 202-205.
[15]	Qian Ping'an, Jiang Yuzi, Nie Hongming. A preliminary study on acupoint application at base of sport exercise in the treatment of patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(2): 206-209.

Prevalence and influencing factors of fatty liver in male employees: A single centre of investigation in a power enterprise

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments